Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on olaparib vs placebo: The SOLO 2/ENGOT Ov-21 trial

被引：18
|
作者：
Frenel, J-S. [1 ,2 ]
Kim, J-W. [3 ]
Berton-Rigaud, D. [1 ,2 ]
Asher, R. [4 ]
Vidal, L. [5 ,6 ]
Pautier, P. [7 ,8 ]
Ledermann, J. A. [9 ,10 ]
Penson, R. T. [11 ]
Oza, A. M. [12 ]
Korach, J. [13 ,14 ]
Huzarski, T. [15 ]
Pignata, S. [16 ,17 ]
Colombo, N. [18 ,19 ,20 ]
Park-Simon, T-W. [21 ,22 ]
Tamura, K. [23 ]
Sonke, G. S. [24 ,25 ]
Freimund, A. [26 ]
Lee, C. K. [27 ]
Pujade-Lauraine, E. [28 ]
机构：
[1] GINECO, Ctr Rene Gauducheau, St Herblain, France
[2] Inst Cancerol Ouest, St Herblain, France
[3] Seoul Natl Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea
[4] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[5] GEICO, Med Oncol, Barcelona, Spain
[6] H Clin Barcelona, Barcelona, Spain
[7] GINECO, Med Oncol, Villejuif, France
[8] Gustave Roussy Canc Ctr, Villejuif, France
[9] NCRI, Dept Oncol, London, England
[10] UCL, London, England
[11] Massachusetts Gen Hosp, Med Oncol, Boston, MA 02114 USA
[12] Princess Margaret Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
[13] ISGO, Dept Gynecol Oncol, Tel Aviv, Israel
[14] Chaim Sheba Med Ctr, Tel Aviv, Israel
[15] Pomeranian Med Univ, Int Hereditary Canc Ctr, Genet & Pathol, Szczecin, Poland
[16] MITO, Dept Urol & Gynecol, Naples, Italy
[17] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy
[18] MaNGO, Gynecol Oncol Dept, Milan, Italy
[19] European Inst Oncol, Milan, Italy
[20] Univ Milano Bicocca, Milan, Italy
[21] AGO, Gynecol Oncol, Hannover, Germany
[22] Hannover Med Sch, Hannover, Germany
[23] Natl Canc Ctr, Dept Breast & Med Oncol, Tokyo, Japan
[24] DGOG, Dept Med Oncol, Amsterdam, Netherlands
[25] Netherlands Canc Inst, Amsterdam, Netherlands
[26] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia
[27] St George Publ Hosp, Canc Care Ctr, Sydney, NSW, Australia
[28] ARCAGY GINECO, Med Oncol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.952
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
813MO
引用
收藏
页码：S615 / S615
页数：1
相关论文
共 50 条
  • [21] First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU)
    Rouge, T. De La Motte
    Pautier, P.
    Alexandre, J.
    Ray-Coquard, I.
    Cottu, P.
    Rodrigues, M.
    Follana, P.
    Floquet, A.
    Lortholary, A.
    Heudel, P. E.
    Combe, P.
    Joly, F.
    Suau, D.
    Maribas, D.
    Licour, M.
    De La Porte, I.
    Varoqueaux, N.
    Pujade-Lauraine, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S548 - S549
  • [22] A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)
    Mirza, M. R.
    Monk, B. J.
    Oza, A.
    Mahner, S.
    Redondo, A.
    Fabbro, M.
    Ledermann, J.
    Lorusso, D.
    Vergote, I. B.
    Rosengarten, O.
    Berek, J.
    Herrstedt, J.
    Tinker, A. V.
    Dubois, A.
    Gonzalez Martin, A.
    Follana, P.
    Benigno, B.
    Rimel, B. J.
    Agarwal, S.
    Matulonis, U.
    ANNALS OF ONCOLOGY, 2016, 27
  • [23] SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
    Wu, X.
    Liu, J.
    Wang, L.
    Lin, Z.
    Wang, J.
    Wang, C.
    Kong, B.
    Liang, Z.
    Cheng, Y.
    Wen, H.
    Lou, G.
    Huang, Y.
    Wang, K.
    An, R.
    Zhu, J.
    Zhou, H.
    Yue, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S521 - S521
  • [24] A Randomized, Double-Blind Phase 3 Trial of Maintenance Therapy With Niraparib vs Placebo in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (ENGOT-OV16/NOVA Trial)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 3 - 5
  • [25] Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.
    Penson, Richard T.
    Valencia, Ricardo Villalobos
    Cibula, David
    Colombo, Nicoletta
    Leath, Charles A.
    Bidzinski, Mariusz
    Kim, Jae-Weon
    Nam, Joo-Hyun
    Madry, Radoslaw
    Hernandez, Carlos Hernandez
    Mora, Paulo Alexandre Ribeiro
    Ryu, Sang Young
    Milenkova, Tsveta
    Lowe, Elizabeth S.
    Barker, Laura
    Scambia, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer
    Mehra, Tarun
    Lupatsch, Judith E.
    Kossler, Thibaud
    Dedes, Konstantin
    Siebenhuner, Alexander Reinhard
    von Moos, Roger
    Wicki, Andreas
    Schwenkglenks, Matthias E.
    PLOS ONE, 2024, 19 (04):
  • [27] Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
    Shu, Yamin
    Liu, Yanxin
    He, Xucheng
    Ding, Yufeng
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [28] Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
    Poveda, A.
    Lheureux, S.
    Colombo, N.
    Cibula, D.
    Lindemann, K.
    Weberpals, J.
    Bjurberg, M.
    Oaknin, A.
    Sikorska, M.
    Gonzalez-Martin, A.
    Madry, R.
    Perez, M. J. Rubio
    Ledermann, J.
    Davidson, R.
    Blakeley, C.
    Bennett, J.
    Barnicle, A.
    Skof, E.
    GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 498 - 504
  • [29] Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
    Tjokrowidjaja, Angelina
    Lee, Chee K.
    Friedlander, Michael
    Gebski, Val
    Gladieff, Laurence
    Ledermann, Jonathan
    Penson, Richard
    Oza, Amit
    Korach, Jacob
    Huzarski, Tomasz
    Manso, Luis
    Pisano, Carmela
    Asher, Rebecca
    Lord, Sarah J.
    Kim, Se Ik
    Lee, Jung-Yun
    Colombo, Nicoletta
    Park-Simon, Tjoung-Won
    Fujiwara, Keiichi
    Sonke, Gabe
    Vergote, Ignace
    Kim, Jae-Weon
    Pujade-Lauraine, Eric
    EUROPEAN JOURNAL OF CANCER, 2020, 139 : 59 - 67
  • [30] Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial (vol 16, pg 87, 2015)
    Oza, A. M.
    Cibula, D.
    Benzaquen, A. O.
    LANCET ONCOLOGY, 2015, 16 (02): : E55 - E55
12345